Compare MNTS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNTS | CGTX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.2M | 79.6M |
| IPO Year | 2019 | 2021 |
| Metric | MNTS | CGTX |
|---|---|---|
| Price | $2.15 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | ★ 555.6K | 473.0K |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,110,000.00 | N/A |
| Revenue This Year | $660.36 | N/A |
| Revenue Next Year | $42.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.55 |
| 52 Week High | $22.20 | $1.83 |
| Indicator | MNTS | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.25 | 28.18 |
| Support Level | N/A | $0.55 |
| Resistance Level | $4.44 | $1.18 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 5.89 | 19.54 |
Momentus Inc is a U.S.-based commercial space company engaged in providing satellites, satellite buses, and in-space infrastructure services. The company offers space transportation, hosted payload, and in-orbit servicing solutions, including last-mile satellite delivery, refueling, inspection, maintenance, and debris removal. It also develops satellite technologies such as solar arrays and propulsion systems, and provides production and operation of small satellites for government, defense, and commercial customers.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).